Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Multiple sclerosis: an overview.

J Julien1, X Ferrer

  • 1Department of Neurology, Hôpital du Haut-Lévêque, Pessac, France.

Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie
|January 1, 1989
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Novel mutations in DNAJB6 cause LGMD1D and distal myopathy in French families.

European journal of neurology·2018
Same author

Highlighting the differences in post-traumatic symptoms between patients with complicated and uncomplicated mild traumatic brain injury and injured controls.

Brain injury·2017
Same author

Association of traumatic brain injury and Alzheimer disease onset: A systematic review.

Annals of physical and rehabilitation medicine·2017
Same author

Parkinsonism in a patient with Leber hereditary optic neuropathy (LHON).

Revue neurologique·2015
Same author

Systemic capillary leak syndrome in an 85-year-old man (Clarkson's syndrome).

Revue neurologique·2014
Same author

Comparison of two HIV testing strategies in primary care centres: indicator-condition-guided testing vs. testing of those with non-indicator conditions.

HIV medicine·2013
Same journal

Corrigendum to "Targeting PD-L1 and disrupting Siglec-9 cooperatively potentiate macrophage phagocytosis of breast cancer via a trispecific macrophage engager (TriME)" [Biomed. Pharmacother. 200 (2026), 119609].

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026
Same journal

Targeted attenuation of liver fibrosis using microbubble-enhanced protease-activated receptor 1 chimeric antigen receptor T cells.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026
Same journal

Euphol targets key oncogenic processes and promotes chemoprevention in organoid and In Vivo models of colorectal cancers.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026
Same journal

CAR-T cell therapy and oncolytic viruses: A synergic approach for advanced GI cancers.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026
Same journal

Corrigendum to "Antidiabetic sitagliptin influences tissue regeneration by affecting progenitor cells" [Biomed. Pharmacother. 189 (2025) 118279].

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026
Same journal

Corrigendum: "Zebrafish as a model to study inflammation: A tool for drug discovery" [Biomed. Pharmacother. 144 (2021) 112310].

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026
See all related articles

Multiple Sclerosis (MS) involves T-lymphocyte and macrophage infiltration in the CNS, leading to immune responses. While the exact cause of T-cell activation in MS remains unknown, targeted therapies show promise.

Area of Science:

  • Neuroimmunology
  • Immunology
  • Pathology

Background:

  • Multiple Sclerosis (MS) is characterized by demyelinating lesions infiltrated by activated T-lymphocytes and macrophages.
  • This immune response leads to oligoclonal immunoglobulin (IgG) synthesis and T-cell migration to the central nervous system (CNS).
  • A loss of suppressor/inducer T-cell subsets contributes to the hyperactive immune state in MS.

Purpose of the Study:

  • To investigate the underlying causes of T-cell activation in peripheral blood in MS.
  • To explore potential antigens targeted in the MS immune response, such as myelin basic protein (MBP).
  • To understand the role of genetic susceptibility (class II MHC) and potential viral triggers in MS pathogenesis.

Main Methods:

  • Review of existing literature on MS immunopathology, including T-cell subsets, antigen targets, and genetic factors.

Related Experiment Videos

  • Discussion of the role of soluble factors like interferon-gamma in modulating immune responses in MS.
  • Consideration of diagnostic tools like MRI in assessing disease progression and correlation with relapses.

    • Main Results:

    • The precise antigen triggering T-cell activation in MS is not definitively known, despite MBP being a candidate.
    • Other myelin antigens can induce similar animal models, and anti-MBP antibodies are found in healthy individuals.
    • MS is an ongoing pathological process, not always directly correlated with clinical relapses, as indicated by MRI findings.

    Conclusions:

    • Current MS treatments modulate the immune response but carry potential toxicity.
    • Monoclonal antibodies offer a promising future strategy for specifically targeting T-cells in MS treatment.
    • Further research is needed to elucidate the etiology of T-cell activation and identify specific antigens in MS.